share_log

HC Wainwright & Co. Reiterates Buy on Panbela Therapeutics, Maintains $16 Price Target

HC Wainwright & Co. Reiterates Buy on Panbela Therapeutics, Maintains $16 Price Target

HC Wainwright & Co.重申买入Panbela Therapeutics,维持16美元的目标股价
Benzinga ·  2023/08/11 12:56

HC Wainwright & Co. analyst Joseph Pantginis reiterates Panbela Therapeutics (NASDAQ:PBLA) with a Buy and maintains $16 price target.

HC Wainwright&Co.分析师约瑟夫·潘特吉尼斯重申潘贝拉治疗公司(纳斯达克:PBLA)的买入,并维持16美元的目标价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发